> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# Cullinan's Two-Step Dosing Cuts Cytokine Storm Rate To 26% In Leukemia Drug Trial
- URL: https://www.bullished.co/cullinans-two-step-dosing-cuts-cytokine-storm-rate-to-26-in-leukemia-drug-trial-b23c0143/
- Published: 2026-11-04T14:32:31.000Z
- Updated: 2026-11-04T14:32:31.000Z
- Description: Patients given two step-up doses of CLN-049 had a 26% rate of cytokine release syndrome, versus 36% on one step-up dose.
- Author: Matteo Parrino
- Tags: SEC Filings, CGEM, Industry: Healthcare

Cullinan Therapeutics, a biopharmaceutical company building T cell engagers for autoimmune diseases and cancer, said a two step-up dosing regimen [cut cytokine release syndrome](https://www.sec.gov/Archives/edgar/data/0001789972/000119312526446348/cgem-20261104.htm?ref=bullished.co) to 26% of patients in its CLN-049 leukemia trial, from 36% on a single step-up dose. The company disclosed the updated data in an [8-K](https://www.bullished.co/learn/8-k-items-explained/) filed Wednesday, ahead of poster presentations at the American Society of Hematology meeting in December.

## Safety: fewer storms, milder ones

Cytokine release syndrome, an inflammatory reaction that T cell engagers can trigger, hit 36% (13 of 36 patients) among those who received one step-up dose, and that group included the trial's only Grade 3 event. With two step-up doses, stepping from 1 or 1.5 µg/kg to 6 µg/kg, the rate fell to 26% (7 of 27 patients), and every event was Grade 1 or Grade 2.

Liver-enzyme (transaminase) elevations dropped to 4% (1 of 27 patients) when the first step-up dose was 1 or 1.5 µg/kg. Across the study, 14% of patients had Grade 3 or worse elevations. The company said the elevations were asymptomatic, reversible and not tied to other liver lab abnormalities.

Neurotoxicity called ICANS was uncommon at 6% (5 of 87 patients), with one Grade 3 event, and all cases were self-limiting. Other Grade 3 or worse events in more than 10% of patients were febrile neutropenia (18%) and pneumonia (12%).

## Response rates at the 12 µg/kg dose

The dose-escalation study enrolled 87 patients, 76 with acute myeloid leukemia and 11 with myelodysplastic syndrome, across 13 cohorts. Of those, 80 could be evaluated for efficacy.

At the 12 µg/kg target dose, the composite complete remission rate was 21% (6 of 29 patients, 2 complete remissions) and the overall response rate was 45%. At 6 µg/kg, the figures were 19% (3 of 16 patients, all complete remissions) and 25%.

Patients at 12 µg/kg who started at 1.5 µg/kg or lower did better: a 26% composite complete remission rate (5 of 19 patients, 2 complete remissions) and a 53% overall response rate.

Two responders stayed on CLN-049 for more than 12 months without further consolidation therapy. Five patients had responses with no measurable residual disease by flow cytometry, and in four more responders the drug served as a bridge to stem cell transplant.

## Phase 2 and the ASH posters

The company said a regimen of 1.5 µg/kg on day one and 6 µg/kg on day four gave optimal immune priming and favorable safety. It will carry the 6 and 12 µg/kg doses into the ongoing Phase 2 trial of CLN-049.

CLN-049, which targets FLT3 on leukemia cells, has Orphan Drug and Fast Track designations from the FDA for relapsed or refractory AML, according to the [press release](https://www.globenewswire.com/news-release/2026/11/04/3395435/0/en/cullinan-therapeutics-announces-presentations-for-cln-049-a-flt3-t-cell-engager-and-velinotamig-a-bcma-t-cell-engager-at-the-68th-ash-annual-meeting.html?ref=bullished.co). Cullinan will show four posters at the meeting in New Orleans, two on CLN-049 and two on velinotamig, its BCMA-targeting engager for autoimmune diseases.

The updated CLN-049 data go on display in [Poster 3385 on December 13](https://www.globenewswire.com/news-release/2026/11/04/3395435/0/en/cullinan-therapeutics-announces-presentations-for-cln-049-a-flt3-t-cell-engager-and-velinotamig-a-bcma-t-cell-engager-at-the-68th-ash-annual-meeting.html?ref=bullished.co), from 6:00 p.m. to 8:00 p.m. in New Orleans.

Learn

- [Item 7.01: Regulation FD disclosure →](https://www.bullished.co/learn/8-k-items-explained/#item-701-regulation-fd-disclosure)  
From 8-K Items Explained: What Every Item Code From 1.01 To 9.01 Tells You, With Examples

### Sources

- [8-K Filing — Cullinan Therapeutics, Inc. (CGEM)](https://www.sec.gov/Archives/edgar/data/0001789972/000119312526446348/cgem-20261104.htm?ref=bullished.co) — SEC EDGAR
- [Exhibit cgem-ex99\_1.htm — Cullinan Therapeutics, Inc. 8-K exhibit](https://www.sec.gov/Archives/edgar/data/0001789972/000119312526446348/cgem-ex99%5F1.htm?ref=bullished.co) — SEC EDGAR
- [Cullinan Therapeutics (CGEM) Wins Trial Clearance, Is The Upside Already Priced In?](https://sg.finance.yahoo.com/news/cullinan-therapeutics-cgem-wins-trial-191200450.html?ref=bullished.co) — Yahoo Finance
- [Cullinan Therapeutics Announces Presentations for CLN-049,](https://www.globenewswire.com/news-release/2026/11/04/3395435/0/en/cullinan-therapeutics-announces-presentations-for-cln-049-a-flt3-t-cell-engager-and-velinotamig-a-bcma-t-cell-engager-at-the-68th-ash-annual-meeting.html?ref=bullished.co) — globenewswire.com